Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

4D Molecular Therapeutics

4D Molecular Therapeutics
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$90M LATEST DEAL AMOUNT
16 INVESTORS
Description

Provider of a transformative discovery platform created for the treatment of serious and unmet medical conditions. The company's transformative gene therapeutic products unlock the full potential of gene therapy field and offers customized AAV vectors that can deliver genes to any cell in the body to eradicate disease, enabling clients to target specific patient tissues in a highly efficient and targeted fashion, while avoiding other tissues and resisting immune clearance (by pre-existing antibodies).

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 5980 Horton Street
  • Suite 460
  • Emeryville, CA 94608
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore 4D Molecular Therapeutics’s full profile, request a free trial.

4D Molecular Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC (Series B) 05-Sep-2018 $90M 00000 Completed Generating Revenue
7. Grant 19-Sep-2017 000 000.00 Completed Startup
6. Grant 01-Sep-2016 00000 000.00 Completed Startup
5. Corporate 07-Jan-2016 000.00 Completed Startup
4. Early Stage VC (Series A1) 13-Oct-2015 000.00 000.00 Completed Startup
3. Early Stage VC (Series A) 12-Aug-2015 000 000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

4D Molecular Therapeutics Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Ecublens, Switzerland 00 000.00 000000000000 000.00
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
000000 Venture Capital-Backed Lebanon, NH 000 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed Paris, France 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 00000000 00000
To view this company’s complete list of competitors, request access »

4D Molecular Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Berkeley Catalyst Fund Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

4D Molecular Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
David Kirn MD Chief Executive Officer, Co-Chairman & Co-Founder
Theresa Janke Co-Founder & Chief Operating Officer
Melissa Kotterman Ph.D Vice President, Discovery & Engineering & Founder
Leisa Johnson Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D Co-Founder, CSO & Co-Chairman

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

4D Molecular Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
Charles Theuer MD Self Board Member 000 0000
David Kirn MD 4D Molecular Therapeutics Chief Executive Officer, Co-Chairman & Co-Founder 000 0000
David Schaeffer Ph.D Self Board Member 000 0000
David Schaffer Ph.D Self Co-Founder, CSO & Co-Chairman 000 0000
Deborah Marshall JD Sidley Austin Board Secretary 000 0000
You’re viewing 5 of 9 board members. Get the full list »